TAF Appeal Letter - 2019
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish Powered byTelemed2U
Powered byTelemed2U

TAF Appeal Letter - 2019

TAF Appeal Letter

As a professional in the field of hepatitis B science and medicine, I have been asked to comment on the use of TAF (tenofovir alafenamide), sold as Vemlidy (Gilead, Foster City, CA), in general as well as recent cases of denial at multiple sites in the U.S. by various insurance companies with events that include removal from formularies with patients being redirected to other medications after being prescribed TAF.

The majority of hepatitis B virus (HBV)-infected patients require life-long therapy, but there are longterm safety concerns with use of first-line oral agents tenofovir disoproxil fumarate (TDF) and entecavir. In two industry-funded phase III trials, researchers investigated the effectiveness and safety of the novel prodrug, TAF (tenofovir alafenamide) to evaluate toxicity compared with TDF as well as efficacy.

Download Letter


Metadata